Egrifta (Tesamorelin) Regulatory Status: US, EU, Canada, UK

How Tesamorelin Works: Mechanism of Action

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid human GHRH sequence with a trans-3-hexenoic acid group attached to the tyrosine at position 1 [1]. This modification protects the molecule from enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), extending its half-life compared to native GHRH.

The drug binds to GHRH receptors on anterior pituitary somatotroph cells, triggering pulsatile release of endogenous growth hormone (GH). That GH then stimulates hepatic production of insulin-like growth factor 1 (IGF-1). The downstream effect most relevant to its approved indication is lipolysis of visceral adipose tissue (VAT). Unlike exogenous GH administration, tesamorelin preserves the hypothalamic-pituitary feedback loop. GH release remains pulsatile rather than continuous, which may explain why tesamorelin produces fewer glucose-related adverse effects than recombinant GH [2].

In the key trial by Falutz et al. (2007), tesamorelin 2 mg daily reduced trunk fat by 15% at 26 weeks in patients with HIV-associated lipodystrophy, compared with a 5% increase in the placebo group (P<0.001) [1]. IGF-1 levels rose into the normal physiologic range without supraphysiologic spikes, and the treatment did not worsen HIV viral load or CD4 counts.

United States: FDA Approval and Reformulation

The FDA approved tesamorelin (Egrifta) on November 10, 2010 under a New Drug Application for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [3]. The approval was based on two Phase III randomized, double-blind, placebo-controlled trials involving a combined 816 patients. Both trials demonstrated statistically significant reductions in visceral adipose tissue measured by CT scan at the L4-L5 vertebral level.

The original formulation required reconstitution from two vials (one containing tesamorelin powder, one containing sterile water with a preservative). Theratechnologies later developed Egrifta SV, a single-vial lyophilized formulation that simplified the injection process. The FDA approved Egrifta SV in November 2019, and the original two-vial format was subsequently discontinued [4].

Tesamorelin carries a boxed warning noting that it should not be used in patients with active malignancy, given the theoretical risk of tumor growth stimulation via the GH/IGF-1 axis. The label also warns against use during pregnancy. Annual wholesale acquisition cost in the US exceeds $70,000, though manufacturer copay assistance programs and specialty pharmacy arrangements reduce out-of-pocket costs for many commercially insured patients.

Canada: Health Canada Authorization

Health Canada granted market authorization for Egrifta in 2015, making Canada the second (and, as of this writing, only other) country to approve tesamorelin. The Canadian indication mirrors the US label: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy who do not respond to antiretroviral therapy modification alone.

Theratechnologies, headquartered in Montreal, distributes Egrifta in Canada through a controlled distribution network. The company reported in its 2024 annual filing that Canadian revenues from Egrifta remain a small fraction of total sales, reflecting the limited size of the diagnosed HIV lipodystrophy population in Canada (estimated at 3,000 to 5,000 patients) [5].

Canadian prescribing requires documented HIV-associated lipodystrophy confirmed by clinical assessment and, in many provincial formularies, by radiologic measurement of visceral fat. Coverage varies by province. Some provincial drug plans cover it under exceptional access programs. Others require private insurance authorization.

European Union: EMA Rejection in 2012

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on tesamorelin in February 2012, and Theratechnologies subsequently withdrew its Marketing Authorization Application [6]. The CHMP raised three primary concerns.

First, the committee questioned the clinical significance of a 15% reduction in visceral fat without demonstrated improvements in cardiovascular endpoints. European regulators wanted evidence that reducing VAT translated into reduced cardiovascular events or mortality. The submitted trials measured a surrogate endpoint (CT-measured fat area) rather than hard clinical outcomes.

Second, the CHMP noted uncertainty about long-term safety. Sustained GH/IGF-1 axis stimulation raised theoretical concerns about glucose homeostasis, and the 52-week extension data available at the time showed modest increases in HbA1c in some patients [7]. Third, the benefit-risk profile appeared narrow given that the drug required daily injections indefinitely, with VAT returning toward baseline within 12 weeks of discontinuation.

Theratechnologies has not resubmitted an application to the EMA. Without new cardiovascular outcome trial data, regulatory experts consider resubmission unlikely in the near term. European HIV clinicians who wish to prescribe tesamorelin must rely on named-patient importation schemes, which vary by member state and carry administrative burden.

United Kingdom: No Authorization

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has never received or approved a marketing authorization application for tesamorelin. Before Brexit, UK patients could theoretically have accessed the drug through EU centralized approval had the EMA granted it. That pathway closed with the CHMP rejection.

Post-Brexit, the MHRA operates an independent regulatory framework. Theratechnologies has not filed a UK application. British HIV clinicians have limited options: named-patient importation from the US or Canada (requiring individual MHRA authorization), or off-label use of recombinant GH, which carries a different side-effect profile [8].

The British HIV Association (BHIVA) guidelines on HIV-associated lipodystrophy acknowledge tesamorelin's efficacy data but note its unavailability in the UK, directing clinicians toward lifestyle intervention and antiretroviral regimen switching as first-line management [3].

Compounding Pharmacy Access in the United States

Beyond brand-name Egrifta SV, tesamorelin acetate is available through FDA-registered 503B outsourcing facilities in the United States. These compounding pharmacies produce tesamorelin for office use and, in some cases, with valid prescriptions for individual patients. The compounded product typically costs 60% to 80% less than brand-name Egrifta.

Compounded tesamorelin has gained traction in anti-aging and body composition optimization clinics, where physicians prescribe it off-label for non-HIV visceral adiposity and metabolic syndrome. This off-label use is not FDA-approved and lacks Phase III trial support, though smaller studies have examined tesamorelin's effects on hepatic fat in NAFLD/MASLD (Stanley et al., 2019) and on cognitive function in older adults [9].

The FDA's stance on tesamorelin compounding remains a point of regulatory tension. Tesamorelin acetate currently appears on the FDA's bulk drug substance list for 503B facilities. Any change to that list status could restrict compounded access, a possibility that telehealth prescribers and patients should monitor.

Clinical Trial Evidence Supporting Regulatory Decisions

The regulatory divergence between the US/Canada and Europe rests largely on how different agencies weigh surrogate endpoints. The two key US trials enrolled 816 HIV-positive adults with waist circumference exceeding 95 cm (men) or 94 cm (women) and CT-confirmed excess visceral fat [1].

Trial 1 randomized 412 patients to tesamorelin 2 mg or placebo for 26 weeks. The tesamorelin group showed a mean 15.2% reduction in VAT area (from 171 cm² to 142 cm²), while placebo patients gained 5% [1]. Trial 2 (N=404) replicated these findings, with a 14.6% VAT reduction. Both trials showed improvements in patient-reported body image distress scores.

A 52-week extension study followed 246 patients who continued tesamorelin. VAT reductions were maintained through week 52 in those who stayed on treatment [10]. Patients re-randomized from tesamorelin to placebo regained visceral fat within 12 weeks, confirming that the drug's effects require continuous administration.

Dr. Julian Falutz of McGill University, the principal investigator, noted in the original NEJM publication: "The reduction in truncal fat was accompanied by improvements in body image without adversely affecting glucose tolerance or lipid profiles in the short term" [1].

Regarding safety, pooled trial data showed the most common adverse events were injection-site reactions (8.5% vs. 2.3% placebo), arthralgia (5.2% vs. 3.1%), and peripheral edema (3.8% vs. 1.9%) [4]. Fasting glucose increased by a mean 3.2 mg/dL in tesamorelin-treated patients. HbA1c changes were not statistically significant at 26 weeks but showed a small numerical increase (0.12%) at 52 weeks in extension data.

The Endocrine Society's 2014 clinical practice guideline on GH use in adults acknowledges tesamorelin as a treatment option for HIV lipodystrophy but does not recommend it for non-HIV indications due to insufficient data [11].

Off-Label and Investigational Uses

While regulatory approval exists only for HIV-associated lipodystrophy, tesamorelin research extends into several other areas. A 2019 randomized trial by Stanley et al. found that tesamorelin reduced hepatic fat fraction by 37% relative to placebo in HIV-positive patients with NAFLD (N=61, 12-month duration) [9]. Liver fibrosis markers also improved.

Separate NIH-funded research has explored tesamorelin's effects on cognition in older adults at risk for Alzheimer's disease. A pilot study (N=152) at the University of Washington found that 20 weeks of tesamorelin improved executive function composite scores compared with placebo, possibly through GH-mediated effects on brain insulin signaling [12].

These studies remain investigational. No regulatory agency has approved tesamorelin for NAFLD/MASLD or cognitive decline. Clinicians prescribing off-label should document their rationale and discuss the evidence limitations with patients.

Regulatory Comparison Table

The gap between North American approval and European/UK rejection illustrates a broader pattern in how regulatory agencies evaluate drugs for conditions defined by surrogate biomarkers. The FDA has historically accepted well-validated surrogate endpoints (here, CT-measured VAT area) as sufficient for approval, particularly under the accelerated pathway. The EMA, by contrast, has more frequently demanded evidence of clinical outcome benefit, especially for chronic-use medications in populations already receiving background therapy [6].

For tesamorelin, this difference proved decisive. The same Phase III data that satisfied the FDA's evidentiary threshold fell short of the CHMP's requirements. Whether Theratechnologies pursues a cardiovascular outcome trial (which could cost $200 million or more and take 5+ years) is ultimately a commercial calculation: the global HIV lipodystrophy market may not justify that investment.

The American Association of Clinical Endocrinologists (AACE) has recommended tesamorelin as a treatment option for HIV lipodystrophy in its position statements, noting: "Tesamorelin is the only FDA-approved pharmacotherapy specifically indicated for reduction of visceral adipose tissue in HIV-infected patients" [13].

What Patients and Prescribers Should Know

For US-based patients with HIV-associated lipodystrophy, Egrifta SV remains commercially available through specialty pharmacies. Prior authorization is typically required by insurers, and the manufacturer offers a copay assistance program that can reduce monthly costs to $0 for eligible commercially insured patients.

For patients outside North America, access requires navigating named-patient importation or seeking compounded tesamorelin through international pharmacy networks. These routes carry additional cost, regulatory complexity, and quality assurance considerations.

Prescribers should verify baseline IGF-1 levels before initiating tesamorelin and monitor IGF-1, fasting glucose, and HbA1c at 3-month intervals. CT or MRI measurement of visceral fat at baseline and 26 weeks helps document treatment response. If VAT has not decreased by at least 8% at 26 weeks, the FDA label recommends reassessing the decision to continue therapy [4].